论文部分内容阅读
作者报道名古屋骨髓移植组采用大剂量化放疗和HLA相配的同胞作异基因骨髓移植(allo-BMT)治疗91例急性白血病,包括急性髓性白血病(AML)48例,急性淋巴细胞白血病(ALL)43例。非缓解期移植28例,缓解期移植63例。结果:1、移植病期与无病生存率(DFS):缓解期移植组于移植后700天DFS为46%,1100天为40%,以后继持在此水平。非缓解期移植组500天DFS<10%,示显著减低(P=0.001)。ALL初次缓解期移植DFS72%,第二次缓解后移植DFS28%,示显著性差异(P=0.05),ALL非缓解期480天DFS13%,显著减低(P=0.01),2、年
The authors reported that the Nagoya bone marrow transplantation group received high-dose chemotherapy and HLA-matched siblings for allogeneic bone marrow transplantation (allo-BMT) for 91 cases of acute leukemia, including 48 cases of acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). 43 cases. 28 cases were transplanted in non-remission period and 63 cases in remission period. Results: 1. Transplantation and disease-free survival (DFS): DFS was 46% in the 700-day transplant group and 40% in the 1100 days after transplantation in the remission period, which was subsequently held at this level. In the non-remission period, the DFS was less than 10% in the 500-day transplant group, indicating a significant reduction (P=0.001). 72% of DFS were transplanted at the time of initial remission, 28% of patients received DFS after the second remission, showing significant difference (P=0.05), DFS13% of 480 days of non-remission period of ALL, and significantly decreased (P=0.01).